Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
$0.62
-6.4%		$0.56
$0.43
▼
$2.04
$11.48M-2.715.56 million shs488,881 shs
iSpecimen Inc. stock logo
ISPC
iSpecimen
$1.29
+2.0%		$1.79
$1.18
▼
$53.20
$3.29M1.62580,009 shs155,695 shs
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$0.00
$0.00
$0.00
▼
$0.15
N/A2.471,522 shs3,450 shs
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
$0.22
-2.2%		$0.32
$0.22
▼
$3.54
$3.70M1.452.58 million shs189,334 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
0.00%+43.51%+23.24%-2.40%-52.96%
iSpecimen Inc. stock logo
ISPC
iSpecimen
0.00%-5.26%-18.18%-54.84%-97.31%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00%-90.00%-90.00%-90.00%-99.10%
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
0.00%-1.32%-21.49%-78.87%-93.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
$0.62
-6.4%		$0.56
$0.43
▼
$2.04
$11.48M-2.715.56 million shs488,881 shs
iSpecimen Inc. stock logo
ISPC
iSpecimen
$1.29
+2.0%		$1.79
$1.18
▼
$53.20
$3.29M1.62580,009 shs155,695 shs
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$0.00
$0.00
$0.00
▼
$0.15
N/A2.471,522 shs3,450 shs
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
$0.22
-2.2%		$0.32
$0.22
▼
$3.54
$3.70M1.452.58 million shs189,334 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
0.00%+43.51%+23.24%-2.40%-52.96%
iSpecimen Inc. stock logo
ISPC
iSpecimen
0.00%-5.26%-18.18%-54.84%-97.31%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00%-90.00%-90.00%-90.00%-99.10%
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
0.00%-1.32%-21.49%-78.87%-93.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
1.50
ReduceN/AN/A
iSpecimen Inc. stock logo
ISPC
iSpecimen
1.00
SellN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00
N/AN/AN/A
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest VIVS, BFRG, ISPC, and TBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/19/2026
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/3/2026
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
iSpecimen Inc. stock logo
ISPC
iSpecimen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
$120K96.25N/AN/A$0.19 per share3.28
iSpecimen Inc. stock logo
ISPC
iSpecimen
$1.93M1.68N/AN/A$14.57 per share0.09
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$225.09M0.00N/AN/A$0.14 per share0.00
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
$130K27.95N/AN/A($0.42) per share-0.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
-$6.50M-$0.46N/AN/AN/AN/A-150.36%-127.98%11/13/2026 (Estimated)
iSpecimen Inc. stock logo
ISPC
iSpecimen
-$10.49M-$56.44N/AN/AN/A-2,445.40%-524.39%-140.42%11/5/2026 (Estimated)
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
-$47.72M-$20.52N/AN/AN/A-336.59%N/A-61.89%11/17/2026 (Estimated)
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
-$13.84M-$4.47N/AN/AN/A-11,016.07%-612.23%-177.02%N/A

Latest VIVS, BFRG, ISPC, and TBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
-$0.11-$0.07+$0.04-$0.07$0.22 million$0.22 million
8/14/2026Q2 2026
iSpecimen Inc. stock logo
ISPC
iSpecimen
N/A-$0.98N/A-$0.98N/A$0.15 million
8/12/2026Q1 2027
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
N/A-$0.25N/A-$0.25N/A$0.02 million
7/14/2026Q4 2026
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
N/A-$2.21N/A-$2.21N/A$0.04 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
N/AN/AN/AN/AN/A
iSpecimen Inc. stock logo
ISPC
iSpecimen
N/AN/AN/AN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/AN/AN/AN/AN/A
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
N/A
10.57
10.57
iSpecimen Inc. stock logo
ISPC
iSpecimen
N/A
0.82
0.82
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/A
1.23
1.06
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
N/A
1.70
1.70

Institutional Ownership

CompanyInstitutional Ownership
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
0.96%
iSpecimen Inc. stock logo
ISPC
iSpecimen
13.62%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
37.63%
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
8.23%

Insider Ownership

CompanyInsider Ownership
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
14.70%
iSpecimen Inc. stock logo
ISPC
iSpecimen
12.20%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
24.50%
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
1718.54 million15.82 millionNot Optionable
iSpecimen Inc. stock logo
ISPC
iSpecimen
72.52 million2.21 millionNot Optionable
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
2001.80 million1.36 millionNo Data
VivoSim Labs, Inc. stock logo
VIVS
VivoSim Labs
1116.59 million16.42 millionN/A

Recent News About These Companies

Critical Survey: Bio-Techne (NASDAQ:TECH) versus VivoSim Labs (NASDAQ:VIVS)
September 27 at 5:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31054916
Analyzing Quantum-Si (NASDAQ:QSI) & VivoSim Labs (NASDAQ:VIVS)
September 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31044317
VivoSim Labs Inc. (NASDAQ: VIVS) Uses Human 3D Biology to Streamline Drug Development
September 23, 2026  |  marketscreener.comM
Critical Review: VivoSim Labs (NASDAQ:VIVS) and Caris Life Sciences (NASDAQ:CAI)
September 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31039391
VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure Problem
September 21, 2026  |  financialcontent.comF
High-Impact Stocks DRK, VIVS, AEMD, GMG in the News
September 17, 2026  |  financialcontent.comF
VivoSim Labs Presents New NAMkind Data At EUROTOX 2026
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691506/vivosim-labs-presents-new-namkind-data-at-eurotox-2026.aspx
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
September 16, 2026  |  financialpost.comF
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363138/37000/en/vivosim-labs-unveils-new-namkind-drug-toxicity-data-at-eurotox-2026-demonstrating-predictive-superiority-in-liver-and-gastrointestinal-safety-across-small-molecules-and-adcs.html
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
September 1, 2026  |  financialpost.comF
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354127/37000/en/vivosim-labs-to-add-rat-liver-model-to-namkind-platform.html
VivoSim Provides Financial and Listing Compliance Update
August 6, 2026  |  financialpost.comF
VivoSim Provides Financial and Listing Compliance Update
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340246/37000/en/vivosim-provides-financial-and-listing-compliance-update.html
VivoSim Labs Sets 2026 Annual Shareholder Meeting Date
July 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/vivosim-labs-sets-2026-annual-shareholder-meeting-date?utm_source=marketbeat.com&utm_medium=referral
VivoSim Labs, Inc. (VIVS)
July 28, 2026  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/quote/VIVS/press-releases/
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
July 21, 2026  |  financialpost.comF
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330426/37000/en/vivosim-enters-china-with-first-commercial-sales-of-namkind-toxicology-screening-and-efficacy-testing-services.html
VivoSim Labs Earnings Estimates, EPS & Revenue | NASDAQ:VIVS
July 16, 2026  |  benzinga.comhttps://www.benzinga.com/quote/VIVS/earnings
Why Vivosim Labs Shares Are Rocketing on Wednesday?
July 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/news/why-vivosim-labs-shares-are-rocketing-on-wednesday/ar-AA27YpW0
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
July 16, 2026  |  financialpost.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bullfrog AI stock logo

Bullfrog AI NASDAQ:BFRG

$0.62 -0.04 (-6.40%)
As of 11:33 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

iSpecimen stock logo

iSpecimen NASDAQ:ISPC

$1.28 +0.03 (+1.98%)
As of 11:32 AM Eastern
This is a fair market value price provided by Massive. Learn more.

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

Telesis Bio stock logo

Telesis Bio NASDAQ:TBIO

$0.0001 0.00 (0.00%)
As of 09/25/2026 09:30 AM Eastern

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

VivoSim Labs stock logo

VivoSim Labs NASDAQ:VIVS

$0.22 -0.01 (-2.23%)
As of 11:32 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas